Dissolution Testing - Planned Revision of the USP Chapter

Recommendation
10/11 September 2025
A "Stimuli to the Revision Process" article on the development and validation of dissolution testing methods has been published in the Pharmacopoeial Forum 40(1). The revision of General Chapter <1092> is planned.
General Chapter <1092> should be read together with the general chapter on "In Vitro and In Vivo Evaluation of Dosage Forms" <1088> and the general chapter on "Validation of Compendial Procedures" <1225>.
According to the title of General Chapter <1092> it seems like the dissolution test comprises a single procedure which can be developed and validated. Yet, the dissolution test actually requires two procedures which have to be performed sequentially. The sample preparation procedure is generally seen as the "dissolution test", which is followed by quantification of the dissolved drug. In the future, the second part will be referred to as "analytical finish". There will thus be greater differentiation between those two development stages.
The proposed sections of the revised chapter <1092> are as follows:
- Introduction
- Preliminary Assessment
- Method Development
- Analytical Finish
- Automation
- Validation
- Acceptance Criteria
A concrete date for the implementation of the proposal hasn't been set yet.
You can find all information on the USP Website of the Pharmacopeial Forum (PF).
Source: USP - www.usp.org
Related GMP News
27.08.2025FDA Warning Letter: Missing Identity Tests, Unverified CoAs, and Inadequate DEG/EG Controls
20.08.2025USP Responds to Comments on Chapter <202> HPTLC Identification of Fixed Oils
13.08.2025USP publishes Comments rereived on Chapter <317>
13.08.2025FDA Issues Warning Letter to Contract Testing Laboratory for Inadequate OOS Investigations
06.08.2025EMA publishes Overview of Comments received on ICH M13B Guideline on Bioequivalence
06.08.2025FDA Warning Letter: Company Voluntarily Ceases Drug Production